RESUMEN
Intravenous recombinant tissue plasminogen activator (rtPA) thrombolysis is the most effective therapy for acute ischemic stroke. Its most serious complication is symptomatic intracerebral hemorrhage. The overall incidence reported in the literature is 6%. It is correlated with the wascular injury and the increased vascular permeability. Some clinical features, imaging and laboratory tests can predict the risks of the complication of intracerebral hemorrhage. The mortality and disability are very high in patients with the complications of intracerebral hemorrhage after thrombolytic therapy, and their prognosis is very poor. This article reviews the classification, incidence, predictive factors, and prognosis of intracerebral hemorrhage after thrombolysis.
RESUMEN
Objective To assess the efficacy and safety of dl-3-butylphthalide on the treatment of acute ischemic stroke. Methods A total of 197 patients who were in the period of 72 hours of first attack of ischemic stroke of internal carotid artery with NIHSS from 5 to 25 scores were enrolled in this multi-center, randomized, double-blind and aspirin-control study. Compound " Dan Shen" was used as a baseline therapy. Results Basical recovery plus significant improvement was seen in 74.7% of the patients in dl-3-butylphthalide group and 60.9% in aspirin group (CMH value 4.0,P=0.047);There was a significant improvement for dl-3-butylphthalide group regarding NIHSS total score, total score difference value and Barthel index on the day 11th and 21st after treatment compared with control group. The main adverse reaction of dl-3-butylphthalide was increased aminotransferase and mainly the slight increase of aspartate aminotransferase, by 4.34% and 0 respectively. Conclusion dl-3-butyiphthalide should be regarded as an effective and safe treatment for ischemic stroke and a treatment without severe side effects.